SELLAS Life Sciences Group Inc. (SLS)

Business: SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States.

IPO Date: 29-Dec-2017

Founder, Pres, CEO & Director: Dr. Angelos M. Stergiou M.D., ScD h.c.

Exec. VP, Gen. Counsel & Sec.: Ms. Barbara A. Wood

Listing: NASDAQ: SLS

Country: United States

Headquarters: New York, NY

Website: https://www.sellaslifesciences.com

Market cap: $46.41 Mln

Revenue (TTM): $2.90 Mln

Earnings (TTM): $-35.04 Mln

Cash: $14.25 Mln

Total Debt: $1.21 Mln

Insider's Holding: 0.09%

Liquidity: Low

52 Week range: $2.10 - 10.82

Shares outstanding: 20,535,600

10 Years Aggregate:

• CFO: $-255.31 Mln
• EBITDA: $-305.83 Mln
• Net Profit: $-327.14 Mln